FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief

Zacks01-09

Pacira BioSciences PCRX announced that the FDA has cleared its application to market a new Smart Tip for the iovera system designed to access the medial branch nerves to manage chronic low back pain. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2502709095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 00:12","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2502709095","market":"us","top_or_hot":-1,"title":"FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief","media":"Zacks","content":"<div>\n<p>Pacira BioSciences PCRX announced that the FDA has cleared its application to market a new Smart Tip for the iovera system designed to access the medial branch nerves to manage chronic low back pain. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/fda-clears-pcrxs-iovera-smart-161200175.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-09 00:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/fda-clears-pcrxs-iovera-smart-161200175.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pacira BioSciences PCRX announced that the FDA has cleared its application to market a new Smart Tip for the iovera system designed to access the medial branch nerves to manage chronic low back pain. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/fda-clears-pcrxs-iovera-smart-161200175.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://finance.yahoo.com/news/fda-clears-pcrxs-iovera-smart-161200175.html","article_id":"2502709095","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502709095","pubTimestamp":1736352720,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Pacira BioSciencesPCRX announced that the FDA has cleared its application to market a new Smart Tip for the iovera system designed to access the medial branch nerves to manage chronic low back pain. Please note that this hand-held medical devicewas added to Pacira’s portfolio following the acquisition of MyoScience.The iovera system is a groundbreaking, FDA-approved, drug-free treatment that alleviates pain through cryoneurolysis. This technique uses targeted cold therapy to temporarily disrupt a nerve's ability to transmit pain signals. Patients usually experience immediate pain relief after treatment, with effects lasting for several months as the nerve naturally regenerates.Per the data readout, patients treated with iovera experienced significantly greater pain reduction, with scores more than 2 points lower on the 0-10 NRS Pain scale at 180 and 360 days compared to RFA. After 360 days of treatment, iovera patients experienced statistically and clinically significant improvements i","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","HALO":"奥洛兹美医疗","BK4139":"生物科技","PCRX":"Pacira Pharmaceuticals","CSTL":"Castle Biosciences, Inc.","BK4007":"制药","BK4196":"保健护理服务","CTMX":"CytomX"},"translate_title":"FDA批准PCRX的新型Iovera智能吸头扩大用于缓解疼痛","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTMX":1,"HALO":1,"PCRX":1,"CSTL":0.9},"content_text":"Pacira BioSciences PCRX announced that the FDA has cleared its application to market a new Smart Tip for the iovera system designed to access the medial branch nerves to manage chronic low back pain. Please note that this hand-held medical device was added to Pacira’s portfolio following the acquisition of MyoScience.\nThe iovera system is a groundbreaking, FDA-approved, drug-free treatment that alleviates pain through cryoneurolysis. This technique uses targeted cold therapy to temporarily disrupt a nerve's ability to transmit pain signals. Patients usually experience immediate pain relief after treatment, with effects lasting for several months as the nerve naturally regenerates.\nPer Pacira, chronic low back pain is a widespread issue in the United States, leading to disability, extended work absences and frequent opioid prescriptions, often resulting in dependency. While millions of Americans seek treatment annually, only a small fraction undergo interventional procedures.  Pacira’s new iovera Smart Tip aims to bridge these gaps and enhance care standards.\nIn the past three months, PCRX’s shares have gained 19.9% against the industry’s 10% decline.\nImage Source: Zacks Investment Research\nMore on the FDA Approval of New Smart Tip for PCRX’s Iovera\nPacira’s iovera portfolio previously included a three-pronged Smart Tip with 8.5-mm 27-gauge needles for superficial nerves and a 90-mm 20-gauge Smart Tip for deeper nerves. It has been widely used to manage knee pain and is also effective for treating pain in the hip, shoulder, chest, foot, ankle and other areas.\nFollowing the latest approval, the new 25-gauge, 180-mm Smart Tip expands treatment capabilities by targeting deeper nerves like the medial branch nerve, specifically addressing chronic low back pain linked to facet-mediated pain. Designed for use with a cannula or introducer, this innovative Smart Tip enables precise ice ball formation around deeper peripheral nerves, enhancing pain management options.\nThe FDA-cleared new iovera Smart Tip provides a promising alternative to traditional treatments like radiofrequency ablation (RFA), which comes with notable drawbacks. Unlike RFA, where pain relief may take 1-2 weeks to manifest, the iovera treatment offers immediate effects. Additionally, RFA's intense heat can damage surrounding tissues and blood vessels, potentially causing painful neuritis (nerve inflammation).\nPacira’s iovera cryoneurolysis also demonstrated significant benefits over RFA treatment for facet-mediated chronic back pain in a randomized pilot study.\nPer the data readout, patients treated with iovera experienced significantly greater pain reduction, with scores more than 2 points lower on the 0-10 NRS Pain scale at 180 and 360 days compared to RFA. After 360 days of treatment, iovera patients experienced statistically and clinically significant improvements in functional outcomes, measured average Oswestry Disability Index (ODI) scores improving from moderate disability to minimal disability. Additionally, more iovera patients reported satisfaction with their pain management compared to those receiving RFA. No serious adverse events were observed throughout the study.\nPCRX’s Other Marketed Products\nApart from the iovera system, Pacira’s marketed portfolio of products comprises two drugs – Exparel and Zilretta.\nExparel is PCRX’s flagship pain-management product, which was initially launched in 2012. The drug is indicated for postsurgical local analgesia in patients aged six years and older. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.\nZilretta, on the other hand, is approved as an extended-release intra-articular therapy providing relief to osteoarthritis (OA) patients with knee pain.\nPacira is also currently looking to expand Zilretta’s indication to include treatment for OA pain in the shoulder. It initiated a phase III study in the first quarter of 2024 to evaluate the efficacy of Zilretta in shoulder OA. Based on the success of the study, the company plans to seek label expansion of the drug for this indication.\n\nPacira BioSciences, Inc. Price and Consensus\n\nPacira BioSciences, Inc. price-consensus-chart | Pacira BioSciences, Inc. Quote\n\nPCRX’s Zacks Rank & Stocks to Consider\nPacira currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX and Halozyme Therapeutics HALO, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 30 days, 2024 estimates for Castle Biosciences’ earnings per share have remained constant at 34 cents. During the same timeframe, loss per share estimates for 2025 have remained constant at $1.84. In three months, shares of Castle Biosciences have gained 11.9%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.\nIn the past 30 days, estimates for Halozyme Therapeutics’ 2024 earnings per share have Improved from $4.05 to $4.07. Estimates for 2025 earnings per share have increased from $4.80 to $4.81 during the same timeframe. In three months, Halozyme Therapeutics’ shares have gained 1%.\nHALO’s earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 14.86%.\nIn the past 30 days, estimates for CytomX Therapeutics’ 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In three months, CytomX Therapeutics’ stock has lost 11.3%.\nCTMX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nHalozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report\nPacira BioSciences, Inc. (PCRX) : Free Stock Analysis Report\nCytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2502709095"}